ImmuPharma (LON:IMM) Trading Down 10% - Time to Sell?

Key Points

• ImmuPharma's share price fell by 10% on Wednesday, with trading volumes increasing significantly to 9.6 million shares.
• The company reported a negative EPS of GBX (0.38) and has a concerning PE ratio of -1,224.72, indicating potential financial struggles.
• ImmuPharma is focused on developing peptide-based therapeutics, with its lead program aimed at treating Lupus and potentially other autoimmune diseases.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price traded down 10% during trading on Wednesday . The stock traded as low as GBX 10.58 ($0.14) and last traded at GBX 10.89 ($0.15). 9,607,201 shares changed hands during mid-day trading, an increase of 12% from the average session volume of 8,569,231 shares. The stock had previously closed at GBX 12.10 ($0.16).

ImmuPharma Trading Down 9.9%

The company has a 50-day simple moving average of GBX 4.66 and a 200 day simple moving average of GBX 3.39. The firm has a market cap of £54.47 million, a PE ratio of -1,224.72 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, equities analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.